234 related articles for article (PubMed ID: 26959614)
1. NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics.
Kumar D; Gupta A; Nath K
Expert Rev Mol Diagn; 2016 Jun; 16(6):651-61. PubMed ID: 26959614
[TBL] [Abstract][Full Text] [Related]
2. High-resolution NMR spectroscopy of human body fluids and tissues in relation to prostate cancer.
Kumar V; Dwivedi DK; Jagannathan NR
NMR Biomed; 2014 Jan; 27(1):80-9. PubMed ID: 23828638
[TBL] [Abstract][Full Text] [Related]
3. Molecular imaging of prostate cancer with PET.
Jadvar H
J Nucl Med; 2013 Oct; 54(10):1685-8. PubMed ID: 24084704
[TBL] [Abstract][Full Text] [Related]
4. NMR-based metabolomics approach to target biomarkers for human prostate cancer.
Jordan KW; Cheng LL
Expert Rev Proteomics; 2007 Jun; 4(3):389-400. PubMed ID: 17552923
[TBL] [Abstract][Full Text] [Related]
5. Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer.
Lucarelli G; Rutigliano M; Galleggiante V; Giglio A; Palazzo S; Ferro M; Simone C; Bettocchi C; Battaglia M; Ditonno P
Expert Rev Mol Diagn; 2015; 15(9):1211-24. PubMed ID: 26174441
[TBL] [Abstract][Full Text] [Related]
6. NMR-Based Prostate Cancer Metabolomics.
Euceda LR; Andersen MK; Tessem MB; Moestue SA; Grinde MT; Bathen TF
Methods Mol Biol; 2018; 1786():237-257. PubMed ID: 29786797
[TBL] [Abstract][Full Text] [Related]
7. Metabolomics-based methods for early disease diagnostics.
Gowda GA; Zhang S; Gu H; Asiago V; Shanaiah N; Raftery D
Expert Rev Mol Diagn; 2008 Sep; 8(5):617-33. PubMed ID: 18785810
[TBL] [Abstract][Full Text] [Related]
8. Innovation in metabolomics to improve personalized healthcare.
Cacciatore S; Loda M
Ann N Y Acad Sci; 2015 Jun; 1346(1):57-62. PubMed ID: 26014591
[TBL] [Abstract][Full Text] [Related]
9. NMR-Based Metabolomics in Gallbladder Cancer Research.
Ranjan R; Sinha N
Methods Mol Biol; 2019; 2037():231-241. PubMed ID: 31463849
[TBL] [Abstract][Full Text] [Related]
10. A decade in prostate cancer: from NMR to metabolomics.
DeFeo EM; Wu CL; McDougal WS; Cheng LL
Nat Rev Urol; 2011 May; 8(6):301-11. PubMed ID: 21587223
[TBL] [Abstract][Full Text] [Related]
11. Metabolomics: a revolution for novel cancer marker identification.
Bu Q; Huang Y; Yan G; Cen X; Zhao YL
Comb Chem High Throughput Screen; 2012 Mar; 15(3):266-75. PubMed ID: 22221059
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer Metabolomics Using NMR.
Sharma U; Jagannathan NR
Methods Mol Biol; 2019; 2037():195-213. PubMed ID: 31463847
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in metabolomics in oncology.
O'Connell TM
Bioanalysis; 2012 Feb; 4(4):431-51. PubMed ID: 22394143
[TBL] [Abstract][Full Text] [Related]
14. Clinical applications of metabolomics in oncology: a review.
Spratlin JL; Serkova NJ; Eckhardt SG
Clin Cancer Res; 2009 Jan; 15(2):431-40. PubMed ID: 19147747
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of patients with and without prostate cancer using urine
Hasubek AL; Wang X; Zhang E; Kobus M; Chen J; Vandergrift LA; Kurreck A; Ehret F; Dinges S; Hohm A; Tilgner M; Buko A; Habbel P; Nowak J; Mercaldo ND; Gusev A; Feldman AS; Cheng LL
Magn Reson Chem; 2023 Dec; 61(12):740-747. PubMed ID: 37654196
[TBL] [Abstract][Full Text] [Related]
16. Nuclear magnetic resonance spectroscopy of human body fluids and in vivo magnetic resonance spectroscopy: Potential role in the diagnosis and management of prostate cancer.
Gholizadeh N; Pundavela J; Nagarajan R; Dona A; Quadrelli S; Biswas T; Greer PB; Ramadan S
Urol Oncol; 2020 Apr; 38(4):150-173. PubMed ID: 31937423
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes.
Salciccia S; Capriotti AL; Laganà A; Fais S; Logozzi M; De Berardinis E; Busetto GM; Di Pierro GB; Ricciuti GP; Del Giudice F; Sciarra A; Carroll PR; Cooperberg MR; Sciarra B; Maggi M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922033
[TBL] [Abstract][Full Text] [Related]
18. Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer.
Yang B; Liao GQ; Wen XF; Chen WH; Cheng S; Stolzenburg JU; Ganzer R; Neuhaus J
J Zhejiang Univ Sci B; 2017 Nov.; 18(11):921-933. PubMed ID: 29119730
[TBL] [Abstract][Full Text] [Related]
19. Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer.
Hansen AF; Sandsmark E; Rye MB; Wright AJ; Bertilsson H; Richardsen E; Viset T; Bofin AM; Angelsen A; Selnæs KM; Bathen TF; Tessem MB
Oncotarget; 2016 Jul; 7(27):42071-42085. PubMed ID: 27276682
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
